New Weight Management Program Q&A
US$ 27.15
glp-1 nausea treatment Medications Infographic PeptideComfort™ - Daily GLP-1 Support
Description
No GLP-1 receptor agonist is currently approved to treat Parkinsons disease
Important considerations include: GLP-1 agonists are generally well-tolerated in people with hypertension They do not typically cause dangerous drops in blood pressure Dehydration from gastrointestinal side effects (nausea, vomiting, diarrhoea) can occasionally affect blood pressure and kidney function, so maintaining adequate fluid intake is important If you take diuretics (water tablets), ACE inhibitors or ARBs for blood pressure, your doctor may monitor you more closely during the initial weeks of GLP-1 therapy Seek medical advice promptly if you experience persistent gastrointestinal symptoms that prevent adequate fluid intake NICE guidance (NG28) supports the use of GLP-1 agonists in people with type 2 diabetes who meet specific criteria, with preference for agents with proven cardiovascular benefits in those with established cardiovascular disease
The difference is more pronounced when evaluating the percentage of patients adhering to a strict glycemic control target [15]
approved final version of manuscript
Chief Financial Officer Karsten Munk Knudsen guided 2025 sales growth of 13% to 21% at constant exchange rates, stating the outlook assumed a reduction in patients on compounded GLP-1 treatments in the second half of 2025
doi: 10.1093/ajcn/69.6.1135
